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Abstract The expression of/3-adrenergic receptors on murine 
lymphoeytes stimulated with concanavalin A was studied. A de- 
crease in 13-adrenoeeptor number on T lymphoeytes and a dimin- 
ished response to specific agonist stimulation at the peak of pro- 
liferatiou was found. The blockade of cell proliferation by tyro- 
sine kinascs or protein kinase C inhibitors reversed the decrease 
in 13-adrenoceptor number. PMA plus ionophore or interleukin-2 
hut not PMA alone were able to induce l]-adrenoceptor down- 
regulation accompanying cellular proliferation. These results 
showed that the intraccllular signals triggered during lymphocyte 
activation are involved in/3-adrenoceptor down-regulation and it 
would represent he loss of a mechanism that exerts negative 
neuroimmune control of cellular proliferation. 
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I. Introduction 
The activation of T cells by specific antigen, mitogen or 
monoclonal antibodies leading to T lymphocyte proliferation 
and differentiation is mediated by a complex series of intracel- 
lular signaling events. The signal transduction pathway is ini- 
tiated by the obligatory activation of tyrosine protein kinases 
(TPK) [1,2]. This results in activation ofphospholipase C (PLC) 
which hydrolyzes membrane inositol phospholipids and gives 
rise to two 2nd messengers, namely inositol triphosphate 
(lnsP3) and diacylglycerol (DAG). InsP 3 increases the concen- 
tration of intracellular calcium and DAG activates distinct 
isoforms of protein kinase C (PKC) which then phosphorylate 
and regulate various downstream targets [1,3]. The distinct 
effects of these two 2nd messengers can be partially mimicked 
by Ca 2+ ionophores, which increase the intracellular free Ca 2+ 
concentration and phorbol esters (for example, PMA) which 
activate PKC [4]. PMA binds to and activates PKC at physiol- 
ogic Ca 2+ concentrations [5] inducing proliferation of human 
peripheral blood lymphocytes [6]. 
Evidence has been accumulating over the past several years 
indicating the participation of the autonomic sympathetic sys- 
tem in the modulation of lymphocyte activity. In fact, several 
studies have identified and characterized fl-adrenergic receptor 
(R) on lymphocytes [7] and showed that their activation could 
exert a control of lymphocyte proliferation by increasing the 
intracellular levels of cyclic AMP (cAMP) [8,9]. Thus we have 
previously described the absence of functional fl-adrenoceptors 
in several hyperproliferative lymphoma cell lines [10,11]. 
*Corresponding author. Fax: (54) (1) 856-2751. 
Furthermore, it was described that fl-adrenergic receptor sites 
are diminished in activated B lymphocytes during the course of 
alloimmunization [12]. 
The present study was undertaken to analyze the role of the 
sympathetic nerve system upon lymphocyte proliferation. We 
here shown that fl-adrenergic expression and function were 
diminished on T lymphocytes timulated with the mitogenic 
lectin concanavalin A (Con A) and that the intracellular path- 
ways triggered during lymphocytes activation are involved in 
fl-adrenergic R down-regulation. 
2. Materials and methods 
2. l. Cell suspensions and culture conditions 
Lymphoid cell suspensions from BALB/c inbred mice lymph nodes, 
as well as nylon wool purified T cells, were prepared aseptically as 
described before [13,14]. Cells were cultured at a concentration of 
I x 106 cell/ml, in RPMI 1640 medium (Gibco Co.) supplemented with 
10% heat-inactivated f tal calf serum, 2 mM glutamine and antibiotics, 
alone or in the presence of one of the stimulators of proliferation: Con 
A (4/lg/ml; Sigma Chemical Co.) or the phorbol ester, phorbol myris- 
tate acetate (PMA, 2 x 10 ~ M; Sigma) alone, together with ionophore 
A23187 (2 x 10 6 M; Sigma) or with 12.5 IU/ml of human recombinant 
IL-2 (rIL-2) (Electro Nucleonics Inc.). For microcultures they were 
settled at a final volume of 0.2 ml in 96-well flat-bottom microtiter 
plates (Corning, NY) and for macrocultures they were kept in T-25 
culture flasks (Corning). Cells were cultured for different imes as 
indicated. Where indicated, inhibitors or anti-Tac monoclonal ntibody 
(anti-IL-2 R, 1 : 10; Becton Dickinson) were added when the culture was 
initiated. 
2.2. Proliji, ration assays 
They were performed in microcultures and in 0.2 ml aliquots of 
macrocultures separated on the indicated times and pulsed for 6 h with 
[3H]thymidine ([3H]TdR (INC, Irvine, CA, USA); 15 Ci/mmol) as de- 
scribed [11]. Results are expressed as stimulation i dex (S.I.) calculated 
as the rate between dpm values in experimental cultures and dpm t¥om 
control values obtained with unstimulated cells. For experimental cul- 
tures performed in the presence of inhibitors, % inhibition (% inh.) was 
calculated as: 
%inh. = I - dpm Con A stimulated cells + inhibitor - dpm control x 100. 
dpm Con A stimulated cells - dpm control 
2.3. [~Sl]Cyanopindolol ([~:51]CYP) binding to intact cells 
2 3 x 106 cells/tube were incubated with [~2sI]CYP (New England 
Nuclear; 2200 Ci/mmol) solutions, 1 300 pM radioligand concentra- 
tion in 50 mM phosphate buffer, made isotonic with NaC1, l0 mM 
MgC1, and 10 -4 M phentolamine. After 30 min incubation at 30°C 
samples were filtered through Whatman GF/C filters as indicated be- 
fore [10] and filters were counted in a Wallac counter. Total binding 
curves were analyzed by computer program LIGAND as already de- 
scribed [10,11]. The non-specific binding parameter fitted by LIGAN D 
from the total binding curves did not differ from those determined 
experimentally using 1 ,uM L-propranolol. 
2.4. Cvclic-A MP production 
8 10 × 10 6 cells/ml were incubated in RPMI 1640 for the indicated 
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times and concentrations, with the fl-agonist (-)-isoproterenol (ISO) or 
with prostaglandin El (PGEI). Samples were prepared and cyclic nucle- 
otides were measured as described before [10,1 l]. 
2.5. Drugs 
The following drugs were used in culture at the final concentrations 
indicated in results. The protein kinase inhibitors 1-(5-isoquinolinesul- 
fonyl)-2-methylpiperazine dihydrochloride (H-7) and N-(2-guanidi- 
noethyl)-5-isoquinoline sulfonamide hydrochloride (HA 1004), and the 
TPK inhibitor genistein [15], were obtained from Seikagaku Kogyo 
(Tokyo, Japan) and from Sigma, respectively. 
2.6. Statistical analysis 
The Student's t-test for unpaired values was used to determine the 
levels of significance. When multiple comparison was necessary after 
analysis of variance, the Student-Newman-Keuls testwas applied. Dif- 
ferences between means were considered significant if P -< 0.05. 
3.  Resu l t s  and  d i scuss ion  
For analyzing the expression of fl-adrenergic R on Con A- 
stimulated T lymphocytes macrocultures of lymph node cells 
were prepared. Cells in macrocultures displayed the same ki- 
netic of proliferation as that expected for Con A stimulated 
microcultures with the peak of proliferation at the third day of 
culture that is coincident with a significant decrease in fl- 
adrenoceptor number (Fig. 1). This was not due to culture 
conditions, as unstimulated cells kept in culture medium for 
3 days showed no reduction in fl-adrenergic R number (Fig. 1) 
and it was similar to the decrease obtained with T lymphocytes 
enriched populations timulated for 3 days with Con A (Bmax: 
401 + 12 sites/cell). It is worth noting that at day 1 of culture, 
no modifications were observed in the maximum number of 
binding sites with respect o the R found in normal T lympho- 
cytes (697 _+ 27 sites/cell) and that the reduction persisted after 
5 days of culture, when proliferating rate was diminished (Fig. 
1). Furthermore, we found a significantly lower response in 
isoproterenol (I';,)) stimulated cAMP production on Con A 
treated cells from 3 days of culture as compared to normal 
lymphocytes (data not shown) or cells from 1 day of culture 
with normal number offl-adrenoceptors, reflecting the reduc- 
tion offl-adrenergic sites (Fig. 2). However, similar responses 
were found in both cases when stimulation was induced by 
prostaglandin E~ (PGE]), another hormone that also activates 
the adenylate cyclase system. These data indicate that the still 
available receptor sites are functional, differently to what oc- 
curs with hyperproliferative c ll lines with reduced number of 
uncoupled fl-adrenergic receptors [10]. This phenomenon 
would probably indicate the loss of a negative control of lym- 
phocyte proliferation as it was previously demonstrated that 
proliferation of spleen lymphocytes was inhibited by increasing 
intracellular cAMP levels [16]. To study if the intracellular 
events that lead to T lymphocyte proliferation were involved 
in this phenomenon the effect of different PK and TPK block- 
ers on proliferation and on fl-adrenergic receptor expression 
was compared. Fig. 3 shows that Con A stimulation was inhib- 
ited in a dose-related manner by the TPK inhibitor genistein 
and a full inhibition was achieved with 20 30 H~ml of the 
inhibitor. Under these conditions fl-adrenergic sites were in- 
creased although to a lower extent than in control normal 
lymphocytes values (Table 1 ). It is worth noting that these doses 
of the inhibitor have no effect on cultured cells viability (% of 
~F 
0.28 
0 8 ~ W ~ H 
Cells Days Binding of IzsI-CYP S.l. 
st imulated of Kd ± S,D. Bmax ± S.D. 
with Culture (pM) (sites/sell) 
O - - -O  i 94.4 ± 5.4 85'9 + 42 2.0 ± 0.5 
Con A 0----0 3 81.4 t 6.8  371 + 48*  100 .3  ± 15.0 
A- - -~ 5 76 .7  ± 7 .6  341 ± 20*  20 .8  ~ 1 .0  
Cont ro l  [ - ] - - -~  3 82 .3  ± 6 .1  772 + 69 
Fig. 1. [~25I]CYP binding to cultured lymph node cells. Cells kept in culture for the indicated ays. stimulated or not with Con A (4 Hg/ml), were 
assayed for [~25I]CYP binding as indicated in section 2. Scatchard plots are representative of 4 experiments. Mean values of K d and B°,~,~ _+ S.D. are 
shown in the Table below the figure together with the stimulation i dex (S. 1.) obtained by [3H]TdR incorporation for comparison. *Differ from control 
value of unstimulated T lymphocytes with P < 0.001. 
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Fig. 2. Measurement of cAMP levels in Con A stimulated lymph node cells. Cells were cultured for 1 or 3 days and cAMP was measured on cells 
alone (Basal; m) or stimulated for 3 or 5 rain with (-)-isoproterenol (ISO: 10 pM) (r~) or with prostaglandin E~ (PGEI; 10 ,uM) (~). Results are 
the mean of 3 experiments performed in triplicate. Differ significantly from the corresponding basal values with: *P < 0.05, **P < 0.01. ISO values 
from day 1 of culture are significantly higher than those obtained at day 3, with: (a) P < 0.01 for ISO 3' and P < 0.05 for 1SO 5'. Non-statistical 
differences were found between peak values of PGE~-stimulated cAMP values from day 1 and 3. 
viable cells with 30/xg/ml was -> 70%). An explanation for the 
incomplete recovery offl-adrenoceptors would be found in the 
fact that this dose ofgenistein was demonstrated to inhibit only 
partially the total TPK activity in T lymphocytes [1]. 
Additionally the possibility that the following steps of lym- 
phocyte activation cascade would be involved, was investigated 
by using PK inhibitors, H-7 and HA1004. H-7 and HA1004 
inhibit PKC and cyclic nucleotide PK, being H-7 more efficient 
in inhibiting PKC than HA1004 [19]. H-7 but not HAl004 (up 
to 20/xM, dose that not affect PKC) inhibited Con A stimulated 
proliferation in a dose-related manner (Fig. 3). 
Moreover, as is shown in Table 1 the expression of/7-adreno- 
ceptors was unaffected and was kept as in control values when 
H-7, but not HA1004, was used at 5/AM, a dose that inhibits 
PKC [17], but only inhibit blast transformation ear to 50% 
(Fig. 3). These results indicate that PKC activation leading to 
proliferation is involved in fl-adrenoceptor down-regulation 
which is not a mere consequence of blast transformation during 
proliferation. 
To investigate in depth PKC involvement in the down-regu- 
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Fig. 3. Effect of TPK and PK inhibitors on Con A-stimulated prolifer- 
ation. Dose response curves showing the effects of the TPK blocker, 
genistein ([~), and the PK inhibitors: H-7 (o) or HA 1004 (©). Drugs 
were added at time zero (when initiation of culture) and cells were 
harvested at the third day after a 6-h long pulse of [3H]TdR. Results 
are the mean % of inhibition of at least 3 experiments + S.D. 
lation offl-adrenoceptors, we analyzed if its activation would 
lead to reduction in /7-adrenergic receptor number. As sus- 
tained activation of PKC is essential for subsequent responses 
such as cell proliferation and differentiation [18], and as PMA 
causes sustained activation of PKC [18,19], its effects upon 
lymph node cell proliferation and fl-adrenergic R expression 
were studied. Studies were not performed on purified T cells 
since it has been shown [20] that mitogenic effects of PMA on 
resting T cells depends on accessory cells and are not observed 
when purified T cells are used. PMA behaves as a weak mitogen 
upon lymph node cell proliferation at third day of culture (SI 
in Fig. 4) as was previously shown in human peripheral blood 
lymphocytes [20]. However, no reduction offl-adrenergic sites 
was found at any time of cell culture (Fig. 4) and even a slight 
increase in fl-adrenergic R sites was found at 3rd day of culture. 
As it was shown that Ca 2+ ionophore acts synergistically with 
phorbol esters to stimulate DNA synthesis and in the activation 
of some isoenzymes of PKC, namely PKCc~ and PKCfl in 
human T cells [21], we studied whether A23187 would act syn- 
ergistically with PMA to induce fl-adrenoceptor down-regula- 
tion. We found that cells cultured for 3 days with A23187 alone 
displayed a slight decrease in fl-adrenoceptor number (613 _+ 36 
sites/cell), that represents not more than 12% reduction with 
respect o normal T cell controls, and no proliferative activity 
Table 1 
Inhibition of Con A-induced decrease in fl-adrenoceptor number by 
PKC and TPK blockers 
Treatment ~ ['25I]CYp binding b
Kd --+ S.D. B ..... 
(pM) (sites/cell) 
Con A 81.4 + 6.8 371 _+ 48 
Con A + genistein (30/.xg/ml) 84.2 + 7.4 616 _+ 37* 
Con A + H-7 (5/xg/ml) 79.6 _+ 5.3 743 + 12" 
Con A + HA 1004 (5 ,ug/ml) 82.7 + 6.9 401 + 16 
"Cells were cultured with Con A alone or in the presence of the indicated 
TPK or PK blockers. After 3 days of culture, cells were washed three 
times and measurement binding of ['251]CYP was performed. 
bK d and Bm,x values were calculated by LIGAND analysis as indicated. 
*Differ significantly from Con A values with P < 0.001. 
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Cells Days Binding of IssI-CYP S.I. 
stimulated of Kd ± S.D. Bmax ± S.D. 
with Culture (pM) (sites/cel l)  
0 - - -0  1 73.0 ± 7.1 843 ± 86 1,5 ± 0.5 
PMA A- - -A 3 78.5 ± 7.5 1023 ± 86 18.8 ± 8.2 
d- - ' -~  5 85 .8  ::1:7.6 782 ± 59 8 .1  ± 1 .6  
PMA 
+ [ - I - - "0  3 73 .1  ± 6.2  349 ± 33*  25 .7  ± 6 .7  
A23187 
Fig. 4. Binding of the fl radioligand [~2Sl]CYP to cells stimulated with PMA or with PMA plus ionophore. Cells were cultured lot the indicated ays 
with 2 nM PMA or for 3 days with 2 nM PMA plus 2 #M A23187 and fl-adrenoceptor expression was checked by [*-~Sl]CYP binding as referred 
to before. The K d, B ...... and S.I. values listed below were obtained as indicated in Fig. 1. *Differ significantly from control or PMA alone with 
P < 0.001. 
was observed (SI = 1.4). However, when lymph node cells were 
incubated with both Ca 2+ ionophore and PMA, a higher prolif- 
erative response and a significant reduction in fl-adrenoceptor 
sites were achieved (Fig. 4), indicating that A23187 acts syner- 
gistically with PMA to induce fl-adrenergic R down-regulation. 
Furthermore, the Ca 2+ blocker verapamil (10 5 M) abrogated 
PMA plus ionophore effects both on proliferation and on fl- 
adrenergic R expression (data not shown). As Ca 2÷ uptake 
seems to play a major role in the events leading to IL-2 produc- 
tion [22,23] and phorbol ester treatment is sufficient for induc- 
tion of the |L-2 R, but synthesis and secretion of IL-2 as well 
as  IL-2 dependent T cell proliferation require the additional 
signal provided by Ca 2+ ionophores [24] the possible participa- 
tion of IL-2 in diminishingfl-adrenoceptor expression was ana- 
lyzed on lymphocyte cultures stimulated with PMA plus rIL-2. 
As is shown in Table 2, rIL-2 addition (12.5 IU/ml) to PMA 
stimulated T cells synergize the proliferative action of PMA 
(S.l.eM A = 19 vs. S.I.I, MA+rIL_ 2 ---- 30) and lead tofl-adrenoceptor 
down-regulation at 3rd day of culture. Furthermore, as it was 
demonstrated that blockade of the IL-2 R by anti-Tac antibody 
inhibited lymphocyte proliferation induced by Con A stimula- 
tion to about 50 88% [25], we analyzed anti-Tac effects on Con 
A induced proliferation and fl-adrenergic R down-regulation. 
Table 2 shows that anti-Tac inhibits Con A proliferative activ- 
ity to 42% and reverted the decrease of fl-adrenergic R sites 
almost to basal values. 
As a consequence of T lymphocyte activation T cells under- 
goes morphologic hanges (blastogenesis) atabout 12 h, divides 
by 24M-8 h and then differentiates as genes are sequentially 
activated for several days [26]. The observed effects upon fl- 
adrenergic receptor expression were not due just to blast trans- 
formation as cells from 1 day of culture showed no reduction 
of fl-adrenoceptor sites. Loss of R might be a result of R 
internalization and degradation as a consequence of mitogen 
induced kinase activation which would lead to fl-adrenergic 
heterologous desensitization. Although this possibility can- 
not be ruled out, it would be difficult to explain the normal 
Table 2 
Participation of II-2 in fl-adrenergic down-regulation 
Treatment a [SH]TdR [125IlCYp 
incorporation b binding c 
(dpm) B ...... 
(sites/cell) 
Basal  1,256 _+ 89 831 + 37 
PMA 23,822 _+ 612 1,131 + 94 
PMA + IL-2 37,985 + 1,760 544 _+ 45* 
Con A 110,371 _+ 1.935 402 + 42** 
Con A + anti-Tac 64.015 _+ 1.129 726 + 33 
~'Cells were cultured for 3 days either alone or in the presence of 2 nM 
PMA; same amount of PMA plus rIL-2 (12.5 U/ml), 4 ,ug/ml Con A 
or also in the presence of anti-Tac (1 : 10 dilution). 
hMean dpm values + S.D. for [3H]TdR incorporated at the third day 
of culture for 3 experiments performed in triplicate. 
~B ...... values were calculated as indicated in Table 1. 
*Differ significantly from PMA values with P < 0.0I. 
**Differ from basal values with P < 0.025. 
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response to fl-agonist stimulation ofcells culture with the mito- 
gen for 1 day, as it was previously shown that heterologous 
desensitization is associated with a rapid functional uncoupling 
of the receptor from the adenylate cyclase system in the absence 
of R sequestration r down-regulation [27]. Another possibility 
is that the observed effects are a consequence of the cascade of 
intracellular biochemical events that transduce the signal across 
the outer membrane into the cell nucleus triggering a genetically 
predetermined program which would include the down-regula- 
tion of fl-adrenoceptors. 
In support of this blockade of TPK activity, the first step of 
T lymphocyte activation induced signal transduction pathway 
inhibits fl-adrenoceptor site reduction at third day of culture. 
Modulation of fl-adrenergic receptor signal transduction by 
TPK was described in fibroblasts [28] and the possibility that 
this modulation would indirectly involve PKC participation 
was not discarded [28]. 
In fact, the direct activation of PKC with PMA has no effect 
on fl-adrenoceptor expression, but PKC synergistic activation 
by phorbol ester plus ionophore mimicked the Con A induced 
reduction in fl-adrenoceptor expression and PKC blockade im- 
paired fl-adrenoceptor down-regulation. Both mitogenic lectin 
and PMA plus ionophore induced IL-2 gene activation [26]. 
However, PMA and other tumor promoters induce prolifera- 
tion via an 1L-2-independent mechanism [20,29]. So the partic- 
ipation of IL-2 in fl-adrenoceptor down-regulation was ana- 
lyzed. IL-2 R blockade on Con A-stimulated lymphocytes im- 
paired fl-adrenoceptor down-regulation, while the addition of 
IL-2 together with PMA to lymphocyte cultures also induced 
the decrease offl-adrenergic binding sites. In support of these 
results, inhibition of TPK by genistein [30] and of PKC by H-7 
[17] inhibit IL-2 secretion and IL-2 R expression in a dose- 
related manner and both inhibitors reverted Con A induced 
fl-adrenergic R down-regulation. 
Evidence offl-adrenoceptor down-regulation as a change in 
the synthesis of R at the gene level was demonstrated byKiely 
et al. [31] in C6 glioma cells, where glucocorticoids induced R 
down-regulation suppressing transcription ofgene encoding for 
the R. 
An increased egradation offl-adrenoceptors would also be 
genetically determined by the cascade of intracellular signals 
triggered uring proliferation. Evidence is now mounting that 
polypeptide ligands and their membrane R may have an impor- 
tant additional signaling role within the cell nucleus [32]. 
The genetic signals triggered by the biochemical cascade of 
intracellular messengers that would be involved in this down- 
regulation are now under study. This phenomenon would im- 
plicate the loss of a mechanism that exerts negative neuroim- 
mune control of cellular proliferation. 
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